ProQR Therapeutics Stock Forecast, Price & News

-0.08 (-1.46 %)
(As of 07/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume400,274 shs
Average Volume1.92 million shs
Market Capitalization$271.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ProQR Therapeutics logo

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.66 out of 5 stars

Medical Sector

753rd out of 4,434 stocks

Pharmaceutical Preparations Industry

349th out of 1,734 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than ProQR Therapeutics?

Wall Street analysts have given ProQR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ProQR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a drop in short interest in June. As of June 15th, there was short interest totaling 1,660,000 shares, a drop of 15.3% from the May 31st total of 1,960,000 shares. Based on an average trading volume of 3,410,000 shares, the short-interest ratio is currently 0.5 days. Approximately 3.1% of the shares of the stock are short sold.
View ProQR Therapeutics' Short Interest

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ProQR Therapeutics

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) issued its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $0.17 million for the quarter, compared to analysts' expectations of $2.40 million.
View ProQR Therapeutics' earnings history

How has ProQR Therapeutics' stock price been impacted by COVID-19?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PRQR shares have decreased by 22.7% and is now trading at $5.41.
View which stocks have been most impacted by COVID-19

What price target have analysts set for PRQR?

4 brokers have issued 1-year price objectives for ProQR Therapeutics' stock. Their forecasts range from $20.00 to $44.00. On average, they anticipate ProQR Therapeutics' stock price to reach $30.40 in the next year. This suggests a possible upside of 461.9% from the stock's current price.
View analysts' price targets for ProQR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 38, Pay $834.33k)
  • Mr. Gerard Platenburg, Co-Founder & Chief Innovation Officer (Age 57)
  • Ms. Smital Shah M.B.A., Chief Bus. & Financial Officer (Age 45)
  • Dr. Naveed K. Shams M.D., Ph.D., Chief Scientific Officer (Age 65)
  • Ms. Sarah Cue Kiely, VP of Investor Relations & Corp. Communications
  • Ms. Sheila Sponselee, VP of HR
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Ms. Bianca Matthee, Head of Manufacturing and Pharmaceutics
  • Mr. Aniz Girach M.D., Chief Medical Officer (Age 54)
  • Ms. Tiffany Burt, Head of Commercial & VP

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $5.41.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $271.61 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53,190,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 150 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected]

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.